

Justin T Jordan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/573774/publications.pdf>

Version: 2024-02-01

74
papers

1,947
citations

331670

21
h-index

289244

40
g-index

78
all docs

78
docs citations

78
times ranked

2515
citing authors

#	ARTICLE	IF	CITATIONS
1	Neurofibromatoses. Hematology/Oncology Clinics of North America, 2022, 36, 253-267.	2.2	8
2	Practical guidance for telemedicine use in neuro-oncology. Neuro-Oncology Practice, 2022, 9, 91-104.	1.6	1
3	Awareness and agreement with neurofibromatosis care guidelines among U.S. neurofibromatosis specialists. Orphanet Journal of Rare Diseases, 2022, 17, 44.	2.7	1
4	Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. Journal of Clinical Oncology, 2022, 40, 492-516.	1.6	261
5	Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. Neuro-Oncology, 2022, 24, 331-357.	1.2	4
6	Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial. Blood, 2022, 139, 2306-2315.	1.4	62
7	Radiation Therapy for Brain Metastases: ASCO Guideline Endorsement of ASTRO Guideline. Journal of Clinical Oncology, 2022, 40, 2271-2276.	1.6	27
8	Genetic testing to gain diagnostic clarity in neurofibromatosis type 2 and schwannomatosis. American Journal of Medical Genetics, Part A, 2022, 188, 2413-2420.	1.2	3
9	Abstract 6084: Recurrent genomic patterns of MPNST evolution correlate with clinical outcome. Cancer Research, 2022, 82, 6084-6084.	0.9	0
10	Understanding barriers to diagnosis in a rare, genetic disease: Delays and errors in diagnosing schwannomatosis. American Journal of Medical Genetics, Part A, 2022, 188, 2672-2683.	1.2	4
11	Phase 2 trial of bavituximab with chemoradiation and adjuvant temozolomide in newly diagnosed glioblastoma.. Journal of Clinical Oncology, 2022, 40, 2030-2030.	1.6	3
12	Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma. Clinical Cancer Research, 2021, 27, 1048-1057.	7.0	129
13	Effective provider-patient communication of a rare disease diagnosis: A qualitative study of people diagnosed with schwannomatosis. Patient Education and Counseling, 2021, 104, 808-814.	2.2	5
14	DINs: Deep Interactive Networks for Neurofibroma Segmentation in Neurofibromatosis Type 1 on Whole-Body MRI. IEEE Journal of Biomedical and Health Informatics, 2021, PP, 1-1.	6.3	1
15	The impact of the COVID-19 pandemic on neurofibromatosis clinical care and research. Orphanet Journal of Rare Diseases, 2021, 16, 61.	2.7	15
16	Clinical, radiological and genomic features and targeted therapy in BRAF V600E mutant adult glioblastoma. Journal of Neuro-Oncology, 2021, 152, 515-522.	2.9	18
17	A rapid genotyping panel for detection of primary central nervous system lymphoma. Blood, 2021, 138, 382-386.	1.4	13
18	Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genetics in Medicine, 2021, 23, 1506-1513.	2.4	290

#	ARTICLE	IF	CITATIONS
19	Multi-center, single arm phase II study of the dual mTORC1/mTORC2 inhibitor vistusertib for patients with recurrent or progressive grade II-III meningiomas.. Journal of Clinical Oncology, 2021, 39, 2024-2024.	1.6	4
20	Validating Techniques for Measurement of Cutaneous Neurofibromas. Neurology, 2021, 97, S32-S41.	1.1	6
21	Opinion & Special Articles: Maximizing Inclusiveness and Diversity Through Virtual Residency Applications and Interviews. Neurology, 2021, 97, 647-650.	1.1	11
22	Contemporary Neuroscience Core Curriculum for Medical Schools. Neurology, 2021, 97, 675-684.	1.1	5
23	mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition. Journal of Biological Chemistry, 2021, 296, 100157.	3.4	8
24	INNV-04. A MULTI-INSTITUTIONAL CLINICAL AND MRI REPOSITORY OF NEUROFIBROMATOSIS TYPE 1-ASSOCIATED PERIPHERAL NERVE SHEATH TUMORS. Neuro-Oncology, 2021, 23, vi105-vi106.	1.2	1
25	NIMG-08. A MULTI-CENTER RADIOMICS-BASED MODEL TO DIFFERENTIATE BETWEEN NEUROFIBROMATOSIS TYPE 1-ASSOCIATED PLEXIFORM NEUROFIBROMAS AND MALIGNANT PERIPHERAL NERVE SHEATH TUMORS. Neuro-Oncology, 2021, 23, vi128-vi129.	1.2	0
26	CTNI-54. A SINGLE ARM PHASE II STUDY OF THE DUAL MTORC1/MTORC2 INHIBITOR VISTUSERTIB PROVIDED FOR SPORADIC PATIENTS WITH GRADE II-III MENINGIOMAS THAT RECUR OR PROGRESS AFTER SURGERY AND RADIATION. Neuro-Oncology, 2021, 23, vi72-vi72.	1.2	0
27	Vascular dysfunction promotes regional hypoxia after bevacizumab therapy in recurrent glioblastoma patients. Neuro-Oncology Advances, 2020, 2, vdaa157.	0.7	8
28	NIMG-07. LONG-TERM FOLLOW-UP OF SCHWANNOMA GROWTH BEHAVIOR IN ADULT NEUROFIBROMATOSIS TYPE 2 AND SCHWANNOMATOSIS PATIENTS USING WHOLE-BODY MRI. Neuro-Oncology, 2020, 22, ii148-ii148.	1.2	0
29	Primary dural lymphomas: Clinical presentation, management, and outcome. Cancer, 2020, 126, 2811-2820.	4.1	24
30	Attracting neurology's next generation. Neurology, 2020, 95, e1080-e1090.	1.1	7
31	The Use of MEK Inhibitors in Neurofibromatosis Type 1-Associated Tumors and Management of Toxicities. Oncologist, 2020, 25, e1109-e1116.	3.7	53
32	Genomics of MPNST (GeM) Consortium: Rationale and Study Design for Multi-Omic Characterization of NF1-Associated and Sporadic MPNSTs. Genes, 2020, 11, 387.	2.4	16
33	MRI changes in patients with newly diagnosed glioblastoma treated as part of a phase II trial with bavituximab, radiation, and temozolomide.. Journal of Clinical Oncology, 2020, 38, 2546-2546.	1.6	0
34	NCOG-44. NEUROLOGIC ASSESSMENT IN NEURO-ONCOLOGY (NANO) SCALE IN A PHASE II STUDY OF PEMBROLIZUMAB OR PEMBROLIZUMAB PLUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA. Neuro-Oncology, 2020, 22, ii138-ii139.	1.2	0
35	CTIM-32. PHASE II AND BIOMARKER STUDY OF PEMBROLIZUMAB OR PEMBROLIZUMAB PLUS BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA PATIENTS. Neuro-Oncology, 2020, 22, ii40-ii40.	1.2	0
36	Successful anti-CD19 CAR T-cell therapy in HIV-infected patients with refractory high-grade B-cell lymphoma. Cancer, 2019, 125, 3692-3698.	4.1	42

#	ARTICLE	IF	CITATIONS
37	First report of quality of life in adults with neurofibromatosis 2 who are deafened or have significant hearing loss: results of a live-video randomized control trial. <i>Journal of Neuro-Oncology</i> , 2019, 143, 505-513.	2.9	14
38	Anticonvulsant prophylaxis and steroid use in adults with metastatic brain tumors: summary of SNO and ASCO endorsement of the Congress of Neurological Surgeons guidelines*. <i>Neuro-Oncology</i> , 2019, 21, 424-427.	1.2	27
39	Characteristics of graduating US allopathic medical students pursuing a career in neurology. <i>Neurology</i> , 2019, 92, e2051-e2063.	1.1	31
40	Anticonvulsant Prophylaxis and Steroid Use in Adults With Metastatic Brain Tumors: ASCO and SNO Endorsement of the Congress of Neurological Surgeons Guidelines. <i>Journal of Clinical Oncology</i> , 2019, 37, 1130-1135.	1.6	22
41	Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. <i>Blood</i> , 2019, 133, 2212-2221.	1.4	207
42	NIMG-66. LONG-TERM FOLLOW-UP OF NEUROFIBROMATOSIS TYPE 1 PATIENTS USING WHOLE-BODY MRI DEMONSTRATES DYNAMIC CHANGES IN INTERNAL NEUROFIBROMA SIZE. <i>Neuro-Oncology</i> , 2019, 21, vi176-vi176.	1.2	0
43	Expanding the clinical phenotype of individuals with a 3-bp in-frame deletion of the NF1 gene (c.2970_2972del): an update of genotype-phenotype correlation. <i>Genetics in Medicine</i> , 2019, 21, 867-876.	2.4	62
44	Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma. <i>Neuro-Oncology</i> , 2019, 21, 596-605.	1.2	25
45	Quality improvement in neurology: Neuro-Oncology Quality Measurement Set. <i>Neuro-Oncology</i> , 2018, 20, 531-537.	1.2	5
46	Quality improvement in neurology. <i>Neurology</i> , 2018, 90, 652-658.	1.1	7
47	Pain correlates with germline mutation in schwannomatosis. <i>Medicine (United States)</i> , 2018, 97, e9717.	1.0	20
48	Temozolomide therapy for aggressive functioning pituitary adenomas refractory to surgery and radiation: a case series. <i>Neuro-Oncology Practice</i> , 2018, 5, 64-68.	1.6	10
49	Hospice utilization in patients with malignant gliomas. <i>Neuro-Oncology</i> , 2018, 20, 538-545.	1.2	33
50	Health literacy assessment in adults with neurofibromatosis: electronic and short-form measurement using FCCHL and Health LiTT. <i>Journal of Neuro-Oncology</i> , 2018, 136, 335-342.	2.9	7
51	INNV-20. UTILITY OF TELEHEALTH FOR SPECIALTY NEUROFIBROMATOSIS (NF) CARE. <i>Neuro-Oncology</i> , 2018, 20, vi142-vi142.	1.2	2
52	CSIG-42. HIGH THROUGHPUT KINOME AND TRANSCRIPTOME ANALYSES REVEAL NOVEL THERAPEUTIC TARGETS IN NF2-DEFICIENT MENINGIOMA. <i>Neuro-Oncology</i> , 2018, 20, vi52-vi52.	1.2	0
53	NIMG-68. MRI CHANGES IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS TREATED AS PART OF A PHASE II TRIAL WITH BAVITUXIMAB, RADIATION, AND TEMOZOLOMIDE. <i>Neuro-Oncology</i> , 2018, 20, vi191-vi191.	1.2	0
54	Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis. <i>BMC Health Services Research</i> , 2018, 18, 668.	2.2	19

#	ARTICLE	IF	CITATIONS
55	Benign Intracranial Tumors. <i>Neurologic Clinics</i> , 2018, 36, 501-516.	1.8	11
56	Genotype-targeted local therapy of glioma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E8388-E8394.	7.1	40
57	EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma. <i>Neuro-Oncology</i> , 2018, 20, 1185-1196.	1.2	22
58	Phase II study of pembrolizumab or pembrolizumab plus bevacizumab for recurrent glioblastoma (rGBM) patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2006-2006.	1.6	49
59	Mind-Body Treatment for International English-Speaking Adults With Neurofibromatosis via Live Videoconferencing: Protocol for a Single-Blind Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2018, 7, e11008.	1.0	35
60	Neurologic assessment in neuro-oncology (NANO) scale in a prospective phase II trial of anti-PD1 antibody, pembrolizumab with or without bevacizumab in patients with recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2037-2037.	1.6	0
61	First report of factors associated with satisfaction in patients with neurofibromatosis. <i>American Journal of Medical Genetics, Part A</i> , 2017, 173, 671-677.	1.2	9
62	First use of patient reported outcomes measurement information system (PROMIS) measures in adults with neurofibromatosis. <i>Journal of Neuro-Oncology</i> , 2017, 131, 413-419.	2.9	13
63	Glioblastoma care in the elderly. <i>Cancer</i> , 2016, 122, 189-197.	4.1	53
64	Neurologic Immune-Related Adverse Events in Oncology Care. <i>JAMA Neurology</i> , 2016, 73, 907.	9.0	4
65	Education Research: Neurology resident education. <i>Neurology</i> , 2016, 86, e112-7.	1.1	25
66	Increased Risk of Cerebrovascular Disease Among Patients With Neurofibromatosis Type 1. <i>Stroke</i> , 2016, 47, 60-65.	2.0	59
67	Safety of pembrolizumab in combination with bevacizumab in recurrent glioblastoma (rGBM).. <i>Journal of Clinical Oncology</i> , 2016, 34, 2010-2010.	1.6	38
68	HCP-12IMPROVING THE EFFICIENCY OF MOLECULAR TESTING FOR EXPEDITED BRAIN TUMOR PATIENT MANAGEMENT AND CLINICAL TRIAL ENROLLMENT. <i>Neuro-Oncology</i> , 2015, 17, v103.4-v104.	1.2	0
69	A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas. <i>Oncotarget</i> , 2015, 6, 16981-16997.	1.8	46
70	Teaching Neuro <i>Images</i> : Brain mass with hilar adenopathy. <i>Neurology</i> , 2014, 82, e161-2.	1.1	2
71	Magnetic Resonance Imaging Observations in Primary Central Nervous System Lymphoma. <i>JAMA Neurology</i> , 2014, 71, 918.	9.0	4
72	International Issues: Obtaining an adult neurology residency position in the United States. <i>Neurology</i> , 2014, 82, e112-5.	1.1	3

#	ARTICLE	IF	CITATIONS
73	Review of <i>Controversies in Neuro-Oncology: Best Evidence Medicine for Brain Tumor Surgery</i> . JAMA Neurology, 2014, 71, 1195.	9.0	0
74	Unrecognized cobalamin deficiency, nitrous oxide, and reversible subacute combined degeneration. Neurology: Clinical Practice, 2014, 4, 358-361.	1.6	12